Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 1.00 | PARK7 (0.54) | PARK7LMNAHTTKDM4EMEN1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1671089 | 1.00 | PARK7 (0.54) | PARK7LMNAHTTKDM4EMEN1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 1.00 | PARK7 (0.54) | PARK7LMNAHTTKDM4EMEN1 | |
| SCHEMBL666087 | 0.85 | PARK7 (0.64) | PARK7LMNAHTTKDM4EMEN1 | |
| SCHEMBL666050 | 0.84 | PARK7 (0.50) | PARK7LMNAHTTKDM4EMEN1 | |
| SCHEMBL666185 | 0.84 | P2RX1 (0.51) | PARK7MEN1KMT2AKCNMA1P2RX1 | |
| SCHEMBL666528 | 0.84 | PARK7 (0.50) | PARK7LMNAHTTKDM4EMEN1 | |
| SCHEMBL665039 | 0.84 | PARK7 (0.50) | PARK7LMNAHTTKDM4ENPC1 | |
| SCHEMBL352816 | 0.84 | PARK7 (0.48) | PARK7LMNAHTTKDM4EMEN1 | |
| SCHEMBL167099 | 0.84 | PARK7 (0.50) | PARK7HTTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873674-B2 | C-Rel inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014047232-A2 | C-REL INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
| CN-103588731-A | Salicylamide derivatives and preparation method thereof | SHENZHEN WANHE PHARMACEUTICAL CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120088827-A1 | Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120015952-A1 | Inhibitors of NF-KB | PROFECTUS BIOSCIENCES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010148042-A1 | OXABICYCLO [4.1.O]HEPT-B-EN-S-YLCARBAMOYL DERIVATIVES INHIBITING THE NUCLEAR FACTOR-KAPPA(B) - (NF-KB) | PROFECTUS BIOSCIENCES, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20070142465-A1 | Macrophage activation inhibitor | SIGNAL CREATION INC. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1219596-B1 | SALICYLAMIDE DERIVATIVES | SIGNAL CREATION INC (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20060183794-A1 | Drug composition containing nf-kb inhibitor | SIGNAL CREATION INC. (JP) | 2006-08-17 | — | — | US | disclosed |
| US-20060167086-A1 | Medicinal composition | SIGNAL CREATION INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006060819-A2 | DHMEQ AS A SENSITIZING AGENT FOR CHEMOTHERAPY AND IMMUNOTHERAPY OF RESISTANT CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1656936-A1 | MACROPHAGE ACTIVATION INHIBITOR | Signal Creation Inc. (JP) | 2006-05-17 | — | — | EP | disclosed |
| EP-1600445-A1 | MEDICINAL COMPOSITION | Keio University (JP) | 2005-11-30 | — | — | EP | disclosed |
| EP-1541139-A1 | DRUG COMPOSITION CONTAINING NF-KAPPA B INHIBITOR | Signal Creation Inc. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6566394-B1 | Useful as anti-inflammatory agents and immunosuppressive agents | MERCIAN CORPORATION (JP) | 2003-05-20 | — | — | US | disclosed |
| EP-1219596-A1 | SALICYLAMIDE DERIVATIVES | MERCIAN CORPORATION (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015952-A1 | Inhibitors of NF-KB | NFKBIA, IKBKB, IKBKG | PARK7 3327/4885LMNA 3191/4885HTT 4538/4885 |
| US-20070142465-A1 | Macrophage activation inhibitor | CD209, MSR1, ARG1 | PARK7 3295/4885LMNA 3392/4885HTT 4670/4885 |
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | REL, NCOR1, CXCR4 | PARK7 3341/4885LMNA 3297/4885HTT 2909/4885 |
| US-20060167086-A1 | Medicinal composition | DHX36, DHX30, FADS2 | PARK7 3453/4885LMNA 2545/4885HTT 1753/4885 |
| US-20060183794-A1 | Drug composition containing nf-kb inhibitor | NFKBIA, NFKB2, NFKB1 | PARK7 3245/4885LMNA 1146/4885HTT 2861/4885 |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | PARK7 3384/4885LMNA 1408/4885HTT 4212/4885 |
| US-20120088827-A1 | Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB) | NFKBIA, NFRKB, IKBKB | PARK7 3595/4885LMNA 3540/4885HTT 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.